Furthermore, innate-like γ∂-T cells can target and kill HBL tumor cells either with the aid of an EpCAM-targeted antibody (71) or by combination therapy with bispecific EpCAM/CD3 antibody and histone deacetylase inhibition (72). The gene discussed is EPCAM; the disease is neoplasm.